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ABSTRACT
Introduction: Sexuality is an important part of people’s
physical and mental health. Patients with heart disease
often suffer from sexual dysfunction. Sexual
dysfunction has a negative impact on quality of life and
well-being in persons with heart disease, and sexual
dysfunction is associated with anxiety and depression.
Treatment and care possibilities seem to be lacking.
Studies indicate that non-pharmacological interventions
such as exercise training and psychoeducation possess
the potential of reducing sexual dysfunction in patients
with heart disease. The CopenHeartSF trial will
investigate the effect of a comprehensive sexual
rehabilitation programme versus usual care.
Methods and analysis: CopenHeartSF is an
investigator-initiated randomised clinical superiority trial
with blinded outcome assessment, with 1:1 central
randomisation to sexual rehabilitation plus usual care
versus usual care alone. Based on sample size
calculations, 154 male patients with impaired sexual
function due to implantable cardioverter defibrillator or
ischaemic heart disease will be included from two
university hospitals in Denmark. All patients receive
usual care and patients allocated to the experimental
intervention group follow a 12-week sexual rehabilitation
programme consisting of an individualised exercise
programme and psychoeducative consultation with a
specially trained nurse. The primary outcome is sexual
function measured by the International Index of Erectile
Function. The secondary outcome measure is
psychosocial adjustment to illness by the Psychosocial
Adjustment to Illness Scale, sexual domain. A number
of explorative analyses will also be conducted.
Ethics and dissemination: CopenHeartSF is
approved by the regional ethics committee (no H-4-
2012-168) and the Danish Data Protection Agency
(no 2007-58-0015) and is performed in accordance
with good clinical practice and the Declaration of
Helsinki in its latest form.
Registration: Clinicaltrials.gov identifier:
NCT01796353.
BACKGROUND
Sexuality is an important part of people’s phys-
ical and mental health.1 2 Patients with cardio-
vascular disease have an increased prevalence
of sexual dysfunction.3–5 The causes of sexual
dysfunction can be related to physical changes
due to the disease, mental changes or adverse
reactions to drugs and other interventions.6 7
Male sexual dysfunction is divided into sexual
interest/desire disorders, ejaculation and orgas-
mic dysfunctions and erectile dysfunction.8
The most common disorder is erectile dysfunc-
tion, deﬁned as the persistent inability to
obtain or maintain an erection which enables
satisfying sexual activity.9 Erectile dysfunction is
associated with age, but can also be triggered
by organic as well as psychogenic conditions
Strengths and limitations of this study
▪ The study has been designed to meet the criteria
for high quality in non-pharmacological rando-
mised clinical trial with central randomisation,
multicentre participation and blinded assessment
and analysis.
▪ We are aware of the subjective nature of the self-
reported primary outcome (International Index of
Erectile Function). Accordingly, we will interpret
data conservatively.
▪ This trial is the first to test the effect of a com-
prehensive approach on sexual dysfuntion in
patients with ischaemic heart disease or implan-
table defibrillators.
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and is often related to vascular disease such as diabetes,
hypertension and heart disease.10 Studies including 33 451
males estimate that erectile dysfunction in varying degrees
exists in 52% of all men, and that age is the most common
variable associated with erectile dysfunction.3–5 The prob-
ability of complete erectile dysfunction in cardiovascular
patients is 39% compared to 10% in the total population
when adjusting for age.3 4 Physical activity is positively asso-
ciated with a lower incidence of erectile dysfunction.5 The
prevalence of sexual dysfunction in patients with heart
disease ranges from 15% up to 89%.1 11–17 Patients with
ischaemic heart disease and patients with implantable car-
dioverter deﬁbrillator, which are two large and growing
patient populations, are especially affected.11 16 18–20 Sexual
dysfunction has a negative impact on quality of life and
well-being in men with cardiovascular disease and sexual
dysfunction is associated with an increase in anxiety and
depression.21–24 The relationship is perceived to be bidirec-
tional, with one element forcing the other.25 26
Standard treatment
Despite the fact that several international guidelines rec-
ommend that health professionals address the topic of
sexuality in patients with heart disease,27 28 this is rarely
practiced.29 30 The consensus or practice on how or where
patients with heart disease and sexual dysfunction should
be treated is lacking, however, some guidelines about the
prescription of phosphodiesterase-5 (PDE-5) inhibitors
exist.6 The PDE-5 inhibitors have an overall success rate of
50–80% of those treated among patients with cardiovascu-
lar disease.6 31 32 PDE-5 inhibitors are generally safe.
Linking PDE-5 inhibitors to cardiac events, large rando-
mised trials and a meta-analysis suggest that they are not
associated with an increase in myocardial infarction or
cardiac events.6 32 In patients with heart disease and no
effect of PDE-5 inhibitors, or where PDE-5 inhibitors are
contraindicated because of treatment with nitrates, there
seems to be no consensus on what treatment should be
offered for sexual dysfunction.
Non-pharmacological treatment potentials
Non-pharmacological interventions possess potential in
reducing sexual dysfunction. Lifestyle factors such as cigar-
ette smoking, hyperlipidaemia and a sedentary lifestyle all
predict erectile dysfunction4 5 and these are the same risk
factors that predict coronary artery disease. A recent
meta-analysis of six randomised trials with 740 patients with
no known heart disease, showed that lifestyle modiﬁcations
such as physical exercise and pharmacotherapy for cardio-
vascular risk factors were associated with a signiﬁcant
improvement in erectile function.33 Furthermore, a rando-
mised trial investigating the effect of exercise training 3 h/
week or more in patients with no heart disease showed a
signiﬁcant result in improving the person’s erectile func-
tion compared with controls with no exercise training.34
We hypothesise that these lifestyle modiﬁcations can also
improve sexual dysfunction in patients with already estab-
lished heart disease. A systematic literature search showed
ﬁve randomised clinical trials which examine the effect of
physical exercise on sexual dysfunction.35–39 Overall, 591
patients with heart disease were included and the effect
was signiﬁcant in three of the ﬁve trials.37–39 However, the
trials are characterised as being of small sample sizes, using
non-validated tools and mainly focusing on the time before
patients return to sexual activity and not on the ability and
quality of the sexual performance. Randomised trials that
address the psychological aspects of sexual dysfunction are
limited in patients with heart disease. However, one rando-
mised trial testing the effect of sexual therapy showed some
promising trends when it comes to improving the fre-
quency and quality of sexual activity in male patients post-
cardiac event beyond the usual cardiac rehabilitation.40
However, due to the limited power of the sample in this
trial, it did not allow the detection of signiﬁcant effects.
The role of pelvic ﬂoor exercises as a treatment of erectile
dysfunction is not tested on patients with heart disease, but
in the general population 40–47% had regained normal
erectile function after 3–4 months of training the pelvic
ﬂoor muscles.41 42 As the condition of sexual dysfunction
often includes both physical and psychological compo-
nents, it is plausible to believe that patients with heart
disease and sexual dysfunction beneﬁt from a comprehen-
sive rehabilitation intervention43 44consisting of a psychoe-
ducational component and an exercise training
component including pelvic ﬂoor exercises.
TRIAL OBJECTIVES
The objective of the CopenHeartSF is to investigate
beneﬁt and harm on the sexual function of male patients
with ischaemic heart disease or patients with implantable
cardioverter deﬁbrillator of a comprehensive sexual
rehabilitation programme, consisting of a psychoeducative
component and a physical exercise component, including
pelvic ﬂoor exercises. The primary hypothesis is that, a
comprehensive sexual rehabilitation programme improves
sexual function, as assessed by the International Index of
Erectile Function (IIEF) questionnaire45 46 in males with
sexual dysfunction and ischaemic heart disease or patients
with implantable cardioverter by 3.5 points in the experi-
mental group compared with the control group after com-
pletion of the programme. The estimated increase in
primary outcome is based on a study that examines the
effect of a physical intervention in patients with cardiovas-
cular disease taking PDE-5 inhibitors.34 The secondary
hypothesis is that sexual function, measured by the sexual
domain in the Psychosocial Adjustment to Illness Scale
(self-reported version; PAIS-SR) questionnaire47 improves
by two points in the experimental group compared with
the control group after completing the programme. The
estimated increase in secondary outcome is based on two
studies that examine the prevalence of sexual dysfunction
in patients with heart failure.48 49
Exploratory analyses will test the hypotheses that compre-
hensive sexual rehabilitation will improve: health-related
quality of life, anxiety and depression, frequency of sexual
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activity, physical capacity measured by peak oxygen uptake
(peak VO2), pelvic ﬂoor muscle strength and endurance
and female assessment of male partner’s erectile
dysfunction.
METHODS
CopenHeartSF is an investigator-initiated randomised clin-
ical superiority trial with blinded outcome assessment, with
1:1 central randomisation to a comprehensive sexual
rehabilitation programme plus usual care or usual care
alone. Based on sample-size calculations, 154 patients will
be recruited from two university hospitals in Denmark. The
CopenHeartSF trial is a part of the overall CopenHeart
project, consisting of several randomised clinical trials
(http://www.CopenHeart.org), designed to develop
evidence-based knowledge of rehabilitation among patients
with complex cardiac conditions. Major parts of the
CopenHeartSF methods section and trial design in this
article are similar to other randomised clinical trials,
CopenHeartIE,50 CopenHeartRFA51 and CopenHeartVR.52
Study population and eligibility criteria
Male patients above 18 years with sexual dysfunction
associated with implantable cardioverter deﬁbrillator or
with ischaemic heart disease veriﬁed by coronary angiog-
raphy, who have a partner, speak and understand
Danish, and provide a written informed consent, are
considered eligible for participation. Exclusion criteria
are patients at intermediate or high risk in relation to
their cardiovascular status according to recommenda-
tions from the Princeton consensus group32 53; those
with diseases in the urinary tract; those who perform
intense exercise more than 3 h a week; patients with
neurological or orthopaedic deﬁcits which prevent train-
ing; patients with cognitive deﬁcits which prevents con-
sultations and patients who are included in ongoing
research prohibiting additional research participation. A
diagram showing the ﬂow of participants through each
stage of the randomised trial will be made (ﬁgure 1).
Experimental intervention
The experimental intervention is a comprehensive sexual
rehabilitation programme. Sexual rehabilitation in this
trial is deﬁned as: a time-bound planned process with
clear goals and means. Sexual rehabilitation is a process
where several actors, including the patient, are working
towards regaining improved sexual functioning and
coping ability according to their sexual function. The com-
prehensive sexual rehabilitation programme contains a
physical exercise component, including training of the
pelvic ﬂoor and a psychoeducational component.
The physical components
Physical exercise
The goal of physical exercise is to achieve an improvement
in the patient’s physical work capacity, and to eliminate
the fear and uncertainty the patient may feel in relation to
sexual activity as a form of physical activity. The physical
exercise intervention is based on The European Society of
Cardiology recommendations for physical activity for car-
diovascular patients.54 The European Society of
Cardiology recommends that all adults promote and main-
tain their ﬁtness, muscle strength, ﬂexibility and bone
health several hours a week. Training must be of high
intensity and of 30 min duration.54 Furthermore, the inter-
vention is supported by European recommendations for
physical training in cardiac patients55 and has been tested
in two large rehabilitation trials, COPE-ICD and
DANREHAB.56 57 A professional physiotherapist with spe-
ciﬁc knowledge of cardiac rehabilitation initiates the phys-
ical exercise programme. Together with the patient, the
physiotherapist plans and prepares a physical exercise
protocol, taking into account the patient’s clinical condi-
tion and physical abilities. Sixty minutes is allocated for
the initial consultation and preparation of individual train-
ing protocol, including pelvic ﬂoor exercise instructions.
Physical exercise is initiated at a physiotherapist-
supervised setting at the Heart Centre, Rigshospitalet.
Using wireless electrodes integrated into t-shirts (Corus-Fit,
CardioCardio and Corus Exercise Assistant, V.2.0.16,
Finland) potential cardiac arrhythmias, ECG abnormalities
such as ST segment changes, T wave alterations, atrial or
ventricular arrhythmias and training intensity levels are
monitored. The training is initiated with two to three man-
datory exercise sessions at Rigshospitalet. Subsequently, the
patients can choose to continue the intensive physical exer-
cise regimen either at Rigshospitalet, or at a local
CopenHeart-certiﬁed facility, supervised by physiothera-
pists, or as supervised home-based training. Supervised
home-based physical training has previously shown similar
results to hospital-based training.58 This ﬁnding has been
conﬁrmed in a Danish setting.59
One session is structured with 10 min warm-up bicycling,
20 min bicycling with increased intensity (cardiovascular
training), 20 min strength exercises and 10 min stretching
and cool-down period. The warm-up session is performed
at the intensity of 11–12 on the Borg scale.60 The 20 min
cardiovascular training is performed as interval training.
Each session is divided into three sections. Each section
contains an intensity of 13–17 on the Borg scale and time
limit (2–15 min) varying between each section; the second
section with longest and highest intensity. A cool-down
period of 5 min is included after 20 min of cardiovascular
training. The strength and strength-related exercises pri-
marily target lower body muscles, and comprise the follow-
ing four exercises: (1) heel rise performed by repetitions
of maximal ﬂexion from standing position; (2) step-up by
using a step bench of 27 cm; (3) leg press standardised,
starting with 90° ﬂexion, hyperextension not accepted; (4)
90° pull-down performed in a cable machine to target
abdominal muscles. For step-ups and heel-rises, weight
load is calculated as a percentage of body weight (5–20%)
and increased throughout the 12 weeks. Load for leg press
is estimated from repetition maximum (RM) testing and
increases from 60% to 70% of 1 RM during 12 weeks of
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training. All exercises are initiated by 2×12 repetitions and
increased through the programme according to standard
guidelines for strength training.61
To achieve cardiovascular adjustment the training
begins with a warming-up period and ends with a cool-
down period. This cardiovascular adjustment has been
shown to reduce the risk of ischaemia and arrhythmia in
connection to physical exercise.44 62 Participants must
mainly exercise in an upright position to decrease left
ventricular ﬁlling pressure and risk of ischaemia or
heart-failure-triggered ventricular arrhythmias.62
Pelvic floor exercise
The bulbocavernosus muscle and the ischiocavernosus
muscle, two superﬁcial pelvic ﬂoor muscles, are active
during erection and enhance rigidity. The bulbocaverno-
sus muscle encircles 33–50% of the base of the penis.41
The pelvic ﬂoor training regimen is inspired by Dorey
et al,63 who have developed a training regimen for male
patients for use in randomised clinical trials. The regi-
ment is developed and tested in a different patient
population, and we have therefore modiﬁed it to ﬁt car-
diovascular patients. Patients are instructed in pelvic
ﬂoor exercises by a skilled physiotherapist. Patients are
instructed to perform their pelvic ﬂoor exercises twice
daily. Studies showed that a few strong or maximum con-
tractions are more effective when it comes to gaining
muscle hypertrophy than several less strong contrac-
tions.63 Patients are instructed to tighten their pelvic
ﬂoor muscles as strongly as possible (as if to prevent
ﬂatus from escaping) three times when lying, three
times when sitting and three times when standing. The
duration of the contraction is up to 10 s each, and
patients are informed to have a 10 s break between
each contraction. The physiotherapist instructs the
patients on how to contract the bulbocavernosus and
ischiocavernosus muscles. In order to ensure that the
right muscles are involved, attention is placed on the
Figure 1 Flow chart.
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ability to lift the scrotum and retract the penis. To
obtain some degree of pelvic ﬂoor muscle endurance,
the patients are encouraged to tighten the pelvic ﬂoor
muscles when walking.
To encourage adherence and monitor compliance
pulse watches (Polar watch) with extended memory and
exercise training logs are handed out. A training log
contains information about physical exercise as well as
pelvic ﬂoor exercise. At the end of the intervention the
training log and the pulse watch are returned and com-
pliance and intensity level are coded independently.
The psychoeducational components
The goal of the psychoeducative intervention is that the
patient learns to interpret and react to relevant physical
and psychological symptoms, learns to cope with anxiety
and fear, including strategies to manage depressive
symptoms and the ability to be sexually active without
fear.
A specially trained nurse is responsible for the psy-
choeducative intervention. The intervention takes a the-
oretical basis of the patient-centred approach where the
emphasis is on support and education. The conversa-
tions are based on a holistic view of the patient and
focus on the handling of life and managing sexual dys-
function. The intervention is targeted at the modiﬁable
parameters that are reported to affect sexual dysfunc-
tion. The psychoeducative intervention is inspired by RR
Parse’s64 ‘Human Becoming Practice Methodologies’
three dimensions which can be described as (1) discuss
and give meaning to the past, present and future; (2)
explore and discuss events and opportunities and (3)
pursue imagined possibilities. According to this theory,
there are three ways to alter its perceived health: creative
ideas, see, hear and feel how a situation could be if it
was lived in a different way; recognising personal pat-
terns and value priorities and shed light on the para-
doxes by looking at incongruence in a situation and
change the view of reality. The nurse is ‘truly present’ in
the process through discussion, quiet contemplation and
reﬂection. The psychoeducative intervention plus phys-
ical exercise was tested in the COPE-ICD trial, with posi-
tive effects on psychological well-being (mental health)
and the general health subscale of the Short Form-36.56
The nurse is trained in the psychoeducative conversation
through teaching and supervision of nurses who have
experience with the ‘Human Becoming Practice
Methodology’ from the COPE-ICD trial. It is based on
the theoretical literature that forms the basis for under-
standing the processes of practice methodology and
existing specialty speciﬁc knowledge about heart disease,
related symptoms and sexology. The supervisor observes
and provides feedback in relation to the methods and
goals of the conversation. The emphasis is on openness
in the interviews and on the nurse’s ability to: be silently
present while the patient talks, ask questions that
encourage reﬂection, let the patient ﬁnd answers and
solutions and contribute with knowledge, provide advice
and guidance when requested and relevant. The train-
ing of the nurse takes place prior to the intervention. In
practice the intervention will be handled by one nurse
with several years of experience working with cardiac
patients and trained in sexology. The sexology experi-
ence is gained in a 2-week intensive course on basic and
clinical sexology including training in sexual therapy.
Supervision from a sexologist is available during the
intervention. The nurse will conduct consultations with
patients individually, and patients are informed that they
are welcome to bring spouses/relatives. The consultation
will take place in a quiet room in an outpatient setting
and last for 45 min. An inspirational guide will form the
basis for the consultations. The guide consists of several
elements and issues (medical, psychosocial, educational
and sexual) that work as inspiration (see box 1).
Usual care
Participants in the experimental group and in the
control group will receive the usual care according to
current guidelines. Usual care is, for patients for whom
it is not contraindicated, treatment with PDE-5 inhibi-
tors. Patients who are candidates for PDE-5 inhibitors
are encouraged to contact their general practitioner in
order to establish the treatment. Use of PDE-5 inhibitors
will be monitored in both intervention groups. To assess
outcome measures, patients in the control group will be
asked to complete questionnaires on equal terms with
participants in the experimental group. In addition,
they will be tested in the form of cardiopulmonary
testing (peak VO2) and pelvic ﬂoor muscle strength and
endurance at baseline and at the end of the trial.
Outcomes and data collection
In order to evaluate the effect of the comprehensive
sexual rehabilitation programme numerous data will be
collected.
Primary outcome
Sexual function will be measured by the IIEF question-
naire after 16 weeks and 6 months. IIEF was developed
in conjunction with the clinical trial programme for sil-
denaﬁl, and has since been adopted as the ‘gold stand-
ard’ measure for efﬁcacy assessment in clinical trials of
Box 1 Inspiration guide for psychoeducational
consultations
A brief medical history
Actual thoughts and questions regarding their heart disease and
sexual function
Sexual dysfunction
Safety issues
Angina or ICD shock
How the sexual problems affect daily live
Provide the patient with recommendations
Relationship
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erectile dysfunction. It has been linguistically validated
in 32 languages including Danish and used as a primary
outcome in more than 50 clinical trials.34 45 46 It consists
of 15 items including ﬁve domains of sexual function:
erectile function, orgasmic function, sexual desire, inter-
course satisfaction and overall satisfaction. The IIEF
meets psychometric criteria for test reliability and valid-
ity, and has a high degree of sensitivity and speciﬁcity.46
The IIEF is self-assessed, which in sexological research is
widely used and well acclaimed.
Secondary outcome
Sexual function is measured by the PAIS-SR sexual rela-
tionship domain.47 The overall PAIS-SR measure psycho-
social adjustment to illness in terms of seven primary
domains of adjustment: Health Care Orientation,
Vocational Environment, Domestic Environment, Sexual
Relationships, Extended Family Relationships, Social
Environment and Psychological Distress. Each PAIS/
PAIS-SR item is rated on a 4-point (0 through 3) scale of
adjustment, with higher ratings indicating poorer adjust-
ment status. The sexual relationship domain evaluates
shifts in the quality of sexual relations due to the current
illness or treatment. It consists of six items and the total
score ranges from 0 to 18. Low scores indicate good
adjustment, and high scores indicate poor adjustment.
Exploratory outcomes
A more extensive evaluation of physical, psychological
and demographic status over time will be performed.
Physical examination will include pelvic ﬂoor strength
and endurance assessed according to the Modiﬁed
Oxford grading scheme which is a manual digital exam-
ination of the pelvic ﬂoor. It is tested and validated and
used in several trials.65 66 Furthermore, physical capacity
will be measured by peak VO2 using cardiopulmonary
exercise testing (Ergo-Spiro CS-200, Schiller, Switzerland)
with measurement of oxygen uptake (VO2), heart rate
(HR, bpm),ventilation rate (l/min), ventilation fre-
quency (number/min), respiratory expiration ratio
(CO2/O2 in %), blood pressure, physical activity level
(METS) and gas exchange (VO2 andVCO2) during pro-
gressive loading and in the following recovery period.
The test is conducted before the training programme
initiates. Intensity performed as a ramp protocol (load
gradually increases) with the initial work load of 25 W
and increased by 12.5 W every minute until exhaustion,
usually but not always, is where the patient’s oxygen
uptake reaches a steady state despite additional load. The
test follows current standards for cardiopulmonary exer-
cise testing.67 The full test procedure is described by
Rasmussen et al.50 Additionally a series of questionnaires,
regarding health-related quality of life, anxiety and
depression and sexual dysfunction are administered
(see table 1).
Blinding
It is not possible to blind the allocated intervention
group for the staff and the participants.72 All physical
testing, data collection and administration will be con-
ducted by blinded staff, however. Statistical analyses and
drawing of conclusions from these will also be con-
ducted blinded to the intervention group.
Sample size and power calculations
We are planning a trial of the continuous response vari-
able IIEF45 46 from independent control and experimen-
tal participants with one control per experimental
participant. In a previous trial the IIEF within each par-
ticipant group was normally distributed with a SD of 6
points.34 If the true difference in the experimental and
control means is 3.5 points, we will need to include 77
experimental participants and 77 control participants
(total 154 participants) to obtain a power of 95%
Table 1 CopenHeartSF—exploratory quantities subjected
to post-hoc analysis
Quantity
Time of
measure
Type of
quantity
Demographic
Age, height, weight Baseline Continuous
Marital, educational,
occupational status
Baseline Categorical
Smoking Baseline Binary (Y/N)
Clinical
Nutritional status (BMI) Baseline Continuous
NYHA classification Baseline Continuous
Type of heart disease Baseline Categorical
Type of sexual
dysfunction
Baseline Categorical
Diabetes mellitus Baseline Binary (Y/N)
Level of physical activity Baseline Categorical
Level of rehabilitation
offered
Baseline Categorical
PDE-5 inhibitor intake,
Level of activity within
the last 4 weeks, level of
sexual activity
Baseline,
W12, W16,
M6
Categorical
Para clinical
Cholesterol level Baseline Continuous
Functional capacity
Peak VO2 Baseline,
W12
Continuous
Pelvic floor strength and
endurance
Baseline,
W12
Continuous
Serious adverse events W12, W16,
M6
Continuous
Questionnaires
SF-3668 HADS69
EQ-5D-5L70 FAME71 Sex
after ICD questionnaire16
Baseline,
W16, M6
Continuous
BMI, body mass index; Eq-5D-5L, EuroQol; FAME, Female
Assessment of Male Erectile Function; HADS, Hospital Anxiety
and Depression Scale; NYHA, New York Heart Association;
PDE-5, phosphodiesterase-5; SF-36, Short Form-36; Y/N, yes/no.
6 Johansen PP, Zwisler A-D, Hastrup-Svendsen J, et al. BMJ Open 2013;3:e003967. doi:10.1136/bmjopen-2013-003967
Open Access
(β=5%) and a type 1 error probability of 5%. Using this
sample size, an SD of 4 points and an alternative hypoth-
esis of a mean difference of 2 points for the secondary
outcome and a type 1 error probability of 5% the corre-
sponding power for the secondary outcome is found to
be 87%.
Study procedure and randomisation
To achieve our estimated sample size of 154 participants,
patients will be identiﬁed from the hospital databases.
Patients will be selected consecutively. Patients with an
implantable cardioverter deﬁbrillator are required to have
the device implanted more than 1 year prior to inclusion
and patients with ischaemic heart disease 1 year from
event and backward. The 1 year limit has been set so that
patients are past their rehabilitation if any is provided.
Patients will receive the IIEF questionnaire45 by mail
including a stamped return envelope. Patients with a score
≤25, the accepted cut-off score46 on the initial screening,
are invited to attend a preliminary interview with the offer
to participate in a randomised clinical trial targeting
sexual problems. The participant information is sent to
the patient along with the invitation. This gives the patient
an opportunity to read the material in advance and to
prepare possible questions. At the initial interview/
meeting it is determined whether the patient meets the
criteria for participating in the trial. If patients are suited
and want to participate they will be randomised to a com-
prehensive sexual rehabilitation programme plus usual
care versus usual care alone. Stratiﬁcation will be accord-
ing to patient group (patients with ischaemic heart disease
or implantable cardioverter deﬁbrillator) and age (≤59 or
≥60 years) and randomised 1:1 to the experimental group
or the control group. Randomisation will be performed
centrally by the trial coordination centre, Copenhagen
Trial Unit, according to a computer-generated allocation
sequence with a variable block size concealed from the
investigators. Allocation to the intervention groups is
carried out when the investigator calls the Copenhagen
Trial Unit. Relevant information (personal identiﬁcation
number, strata, etc) is typed into a computer system, and
then the participant will be allocated to an intervention
group and awarded a four-digit randomisation number.
The investigator then informs the patient of the result and
on how to proceed by letter. Thus, neither investigators
nor patients or relatives can inﬂuence to which group the
patients are allocated. For both groups, follow-up assess-
ment will take place after 12 weeks (only physical evalu-
ation), 16 weeks and 6 months. Questionnaires will be
completed electronically in the questionnaire system
Enalyzer with ‘single user’, which meets the data legisla-
tion for logging. At inclusion, the trial participant will
receive an email with a link to a website through which
questionnaires can be completed. The email contains a
login and password for the trial participant’s personal
access. The participant has the opportunity to go through
the website http://www.copenheart.org and enter with the
login and password. If patients do not complete the
questionnaire electronically, the material can be sent in
paper form and an independent trial personnel then
enters the responses into the database. Thus data manage-
ment is handled independently from the researchers who
interpret the data. All data are stored electronically in a
coded database, and in an independent spread sheet, only
accessible for the CopenHeart group. The recruitment
process will continue until the number of 154 has been
reached.
Statistical analysis
Analysis of primary and secondary outcomes
The analysis will be performed according to the
intention-to-treat analysis with two-sided signiﬁcance
tests at the 0.05 level. Both outcomes (and outcomes
subjected to exploratory analyses) will be analysed using
the same procedure. First, we will test if there is an
immediate effect of the intervention on the outcome
and/or a difference in the response to the intervention
between the two patient groups (patients with ischaemic
heart disease and patients with implantable cardioverter
deﬁbrillator) using model 1 below. Then the follow-up
data will be included in the analysis and the long-term
effect will be studied using model 2.
Models and analytical techniques
Model 1 The equation (equation 1) showing the depend-
ent variable Y (the outcome) as a function of covariates
used in the analysis of the immediate effect of the inter-
vention on the primary outcome is
Y ¼ interceptþaYbaseline þ bIþcGþ dI :G ð1Þ
Ybaseline is the baseline value of the outcome, I the indi-
cator of intervention, G the indicator of patient group,
and a through d are coefﬁcients to be estimated. The
term dI:G stands for interaction between the two covari-
ates I and G. If the term bI is signiﬁcant (the coefﬁcient
b differs signiﬁcantly from 0) there is an effect of the
intervention common for the two patient groups
(ischaemic patients and patients with implantable cardi-
overter deﬁbrillator). If the term dI:G is signiﬁcant
there is an additional effect of the intervention in one
of the two patient groups; thus a subgroup analysis is
warranted. In the analysis of the data the univariate
general linear model is used. The analysis of the
primary outcome is the primary analysis. The subgroup
analysis and the analysis of the secondary and of other
outcomes should be considered exploratory.
Model 2 In the analysis of follow-up data the time T (Y
is measured 16 weeks and 6 months following random-
isation) is included and the mixed model for repeated
measures is used. The equation (equation 2) for the
ﬁxed effect in this model showing Y as a function of the
covariates is
Y ¼intercept þ aYbaseline þ bGþ cI
þ dI :Gþ eTþ fI :Tþ gI :T :G ð2Þ
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where a through g are coefﬁcients to be estimated. If
the term eT is signiﬁcant there is a linear trend over
time common for both patient groups. If fI:T is signiﬁ-
cant, this trend is supplemented by an additional trend
caused by the intervention and therefore speciﬁc for the
intervention group. If in addition gI:T:G is signiﬁcant
this added trend differs between the two patient groups
(patients with ischaemic heart disease and patients with
implantable cardioverter deﬁbrillator). In the mixed
model analysis an unstructured covariance matrix will be
assumed. If convergence is not attained simpler covari-
ance structure models will be assessed guided by
Akaike’s criterion or the maximum likelihood test as
appropriate.
Missing values
If the number of missing cases for a given outcome
(number of patients with one or more model variables
missing) is larger than 5% or p of Little’s test is <5%
multiple imputations of the model variables (outcome
plus covariates) is performed using SPSS V.17. The
range of potential bias in case the missing values should
not be random is assessed by doing two imputations (1)
imputing missing outcome value in one group by
minimum value found in the material and missing
outcome value in the other group by maximum value
found in material and (2) vice versa. Then in each case
an unadjusted analysis is performed to estimate the par-
ameter of interest.
ETHICS AND DISSEMINATION
The trial complies with the latest Declaration of Helsinki
and is registered at ClinicalTrials.gov (NCT01796353).
Patients are informed about the trial in writing as well as
verbally and only included if a written informed consent is
obtained. Patients are assessed in accordance to whether it
is safe for them to perform sexual activity. This is carried
out according to recommendations from the Princeton
consensus group.32 53 If patients are suited and want to
participate they will be enrolled in the trial. Trial partici-
pants are free to withdraw their informed consent at any
time and be treated according to the departments’ stand-
ard treatment procedures. A patient will be withdrawn
from the trial if the trial participant withdraws his consent
and will, in connection therewith, be informed that ter-
mination of the trial will have no implications for his
future treatment. Patients who leave the trial will be
politely asked for permission to continue to collect data
and to use already collected data. If the patient gives per-
mission, he will be included in the ﬁnal analysis. Only if
the patient refuses use of already collected data, will all
data relating to him be destroyed. All patient data will be
handled and stored in accordance with Danish Data
Protection Agency rules and patients are ensured anonym-
ity. The trial will be conducted according to the Act
No. 593 of 14 June 2011 on Act on Research Ethics
Review of Health Research Projects. The investigator will
immediately notify the regional ethics committee if, within
the interventions period, there occur serious adverse
events, serious adverse reactions or suspected unexpected
serious adverse reactions. The report will be accompanied
by comments on possible implications for the trial, and
notiﬁcation will be made within 7 days after the investiga-
tor has knowledge of the event. The trial has no data mon-
itoring committee however an internal monitor will
perform random checks to see if the trial staff work
according to the protocol. No risks are anticipated to
occur during the sexual rehabilitation programme. As far
as we know, there is no previous risk associated with
nursing consultations. If the nurse, during the consult-
ation, identiﬁes a need for further consultations with pro-
fessionals, she will encourage the participant to seek help
from the general practitioner, psychologist or in their
usual outpatient setting. Risks associated with exercise
training and testing are sudden cardiac death associated
with ventricular arrhythmias, acute myocardial infarction,
and in patients with chronic heart failure, pulmonary
oedema and deterioration in left ventricular function.73
The last is only found in one study from 198874 and has
not subsequently been demonstrated in larger studies.75 76
In a recent French study of more than 25 000 patients with
ischaemic heart disease, one-third with chronic heart
failure found the risk of cardiac complications at 1:8500
exercise testing and 1:50 000 patient exercise hours.77
Increasing exercise intensity and age are risk indicators.
Therefore, the training intensity will be conducted as mod-
erate high intensity (less than 80% of VO2 max). To
achieve cardiovascular adjustment exercise training as well
as testing begins with a warming-up period and ends with
a cool-down period, with a gradual downward adjustment
of exercise intensity and HR, rather than an abrupt end.
This cardiovascular adjustment has been shown to reduce
the risk of ischaemia and arrhythmia in connection with
physical exercise.44 62 Participants must mainly exercise in
an upright position to decrease left ventricular ﬁlling pres-
sure and risk of ischaemia or heart failure triggered ven-
tricular arrhythmias. When these precautions are
respected, exercise training as well as exercise testing are
considered to possess a low risk for the participants. There
is, as far as we know, no previously known risk associated
with pelvic ﬂoor exercise. Testing or examination of the
pelvic ﬂoor may be associated with discomfort for the par-
ticipants but is not considered to be associated with any
risk. Staff members will be trained according to guidelines
to handle any emergencies.
Dissemination plan
Positive, neutral and negative results of the trial will be
submitted to international peer reviewed journals of
nursing, cardiology or sexology. Furthermore, results will
be presented at national and international conferences
relevant to subject ﬁelds. Authorship will be allocated
using the guidelines for authorship deﬁned by the
International Committee of Medical Journal Editors and
depends on the personal involvement. All the articles,
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abstracts as well as the results will be posted on the
website http://www.copenheart.org. The website will be
continuously updated and will be highlighted through
the scientiﬁc articles. CopenHeart staff will have
access to data. Ethic committees and competent author-
ities will be able to obtain direct access to data and
documentation.
DISCUSSION
This randomised clinical trial testing the effect of a com-
prehensive sexual rehabilitation intervention on a popula-
tion of patients with implantable cardioverter deﬁbrillator
or patients with ischaemic heart disease seems to be the
ﬁrst one in its ﬁeld. The trial is expected to contribute
with results that can improve patients’ problems related to
heart disease and sexual function. Additionally, it is
believed that the trial can provide a systematic approach
that may 1 day inform national consensus on how to treat
sexual dysfunction in heart patients. Furthermore, the
results of the trial are expected to contribute to the inter-
national debate on sexual rehabilitation of patients with
heart disease.
The trial is designed with central stratiﬁed randomisa-
tion which secures against selection bias.78 79 The
primary outcome is assessed blinded to intervention and
so are all statistical analysis, which should reduce detec-
tion and interpretation bias.78 79
Trajectory
Inclusion was initiated on February 2013 and is expected
to continue until June 2014.
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